Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
10 November 2005Website:
http://opusgtx.comNext earnings report:
13 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 01 Nov 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
OCUP Latest News
The resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD) RALEIGH, N.C. , Oct. 25, 2024 /PRNewswire/ -- The RD Fund (Retinal Degeneration Fund) – the venture arm of the Foundation Fighting Blindness – announces the all-stock acquisition of Opus Genetics, Inc. "Opus" (private) by Ocuphire Pharma, Inc., (Nasdaq: OCUP) a clinical-stage ophthalmic biopharmaceutical company.
Published data from two Phase 3 clinical trials demonstrated rapid reversal of pharmacologically-induced mydriasis with favorable safety profile Published data from two Phase 3 clinical trials demonstrated rapid reversal of pharmacologically-induced mydriasis with favorable safety profile
CEO to participate in ARVO SIG panel on oral medications for retinal diseases ZETA-1 Phase 2 clinical trial subset analysis to be presented during the ASRS 42 nd Annual Scientific Meeting FARMINGTON HILLS, Mich., July 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced it will participate in the Association for Research in Vision and Ophthalmology Special Interest Group (ARVO SIG) panel and the American Society of Retina Specialists (ASRS) 42 nd Annual Scientific Meeting, to highlight the potential of its lead oral candidate in development for diabetic retinopathy (DR).
FARMINGTON HILLS, Mich., June 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that clinical updates on the Company's lead candidate APX3330 for diabetic retinopathy (DR) will be featured in upcoming presentations at the Clinical Trials at the Summit meeting on June 8 in Park City, Utah, and the Retinal Imaging Biomarkers & Endpoints Summit meeting June 25-27 in Boston.
Here, we discuss some reasons why buying Ocuphire Pharma (OCUP) stock now may turn out to be a prudent move.
Viatris Inc. VTRS, and Ocuphire Pharma Inc. OCUP, +3.08% said Wednesday that the U.S. Food and Drug Administration has approved Ryzumvi to treat the side effects of pharmacologically-induced mydriasis, or dilation of pupils. About 100 million eye dilations are conducted in the U.S. each year to examine the retina and for other routine check-ups, the companies said in a release, but the dilation can last up to 24 hours and side effects include light sensitivity and blurred vision.
Ocuphire Pharma Inc OCUP was plunging over 22% at one point on Friday after the company announced it appointed Rick Rodgers to the role of interim CEO. An SEC filing, which stated former CEO Mina Sooch was terminated suggested there could be an issue at the company, which sparked fear.
The consensus price target hints at a 257.1% upside potential for Ocuphire Pharma, Inc. (OCUP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Ocuphire Pharma, Inc. (OCUP) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Does Ocuphire Pharma, Inc. (OCUP) have what it takes to be a top stock pick for momentum investors? Let's find out.
What type of business is Ocuphire Pharma?
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
What sector is Ocuphire Pharma in?
Ocuphire Pharma is in the Healthcare sector
What industry is Ocuphire Pharma in?
Ocuphire Pharma is in the Biotechnology industry
What country is Ocuphire Pharma from?
Ocuphire Pharma is headquartered in United States
When did Ocuphire Pharma go public?
Ocuphire Pharma initial public offering (IPO) was on 10 November 2005
What is Ocuphire Pharma website?
https://opusgtx.com
Is Ocuphire Pharma in the S&P 500?
No, Ocuphire Pharma is not included in the S&P 500 index
Is Ocuphire Pharma in the NASDAQ 100?
No, Ocuphire Pharma is not included in the NASDAQ 100 index
Is Ocuphire Pharma in the Dow Jones?
No, Ocuphire Pharma is not included in the Dow Jones index
When was Ocuphire Pharma the previous earnings report?
No data
When does Ocuphire Pharma earnings report?
The next expected earnings date for Ocuphire Pharma is 13 November 2024